6-24-2000

c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATc1

Chi-Wing Chow
University of Massachusetts Medical School

C Dong

Richard A. Flavell

See next page for additional authors

Follow this and additional works at: http://escholarship.umassmed.edu/oapubs

Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Repository Citation

Chow, Chi-Wing; Dong, C; Flavell, Richard A.; and Davis, Roger J., "c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATc1" (2000). Open Access Articles. 1436.
http://escholarship.umassmed.edu/oapubs/1436

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATc1

Authors
Chi-Wing Chow, C Dong, Richard A. Flavell, and Roger J. Davis
c-Jun NH2-Terminal Kinase Inhibits Targeting of the Protein Phosphatase Calcineurin to NFATc1

CHI-WING CHOW,1 CHEN DONG,2 RICHARD A. FLAVELL,2 AND ROGER J. DAVIS1*

Howard Hughes Medical Institute, Program in Molecular Medicine, Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605,1 and Howard Hughes Medical Institute, Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 065202

Received 10 January 2000/Returned for modification 24 February 2000/Accepted 12 April 2000

The purpose of this study was to examine the role of JNK1 in NFATc1 regulation. Since the phenotype of Jnk1−/− mice suggests a correlation between the JNK1 signaling pathway and NFATc1 (15), we tested whether NFATc1 is directly regulated by JNK1. We report that JNK1 binds and phosphorylates NFATc1 on sites located near the PxIxIT calcineurin targeting domain (8). Together, these data indicate that the calcineurin targeting domain is a critical component of the regulatory mechanism that controls NFAT activity.

* Corresponding author. Mailing address: Howard Hughes Medical Institute Program in Molecular Medicine University of Massachusetts Medical School, 373 Plantation St., Worcester, MA 01605. Phone: (508) 856-6054. Fax: (508) 856-3210. E-mail: Roger.Davis@Umassmed.edu.

MATERIALS AND METHODS

Reagents. The IL-4 luciferase reporter plasmid (36) and the expression vectors for calcineurin (28), NFATc1 (18), NFATc1−/− (dnNFAT) (8), and JNK signaling pathway components (7, 40) have been described elsewhere. The NFATc1-β expression vector was constructed by cloning a PCR-derived CDNA in the BamHI site of pSRα. Recombinant NFAT proteins were expressed using the vector pGEX-5X1 (Amersham-Pharmacia Biotech) by cloning CDNA fragments in the BamHI and NotI sites. Deletion and point mutations were constructed by PCR and sequenced with an Applied Biosystems machine. Bacterially expressed CRM1 was purified by glutathione (GSH) affinity chromatography (43). The phosphospecific NFATc1 antibody prepared by immunization of rabbits with ovalbumin conjugated with glutaraldehyde to the synthetic phosphopeptide Ala-Pro-Ala-Leu-Glu-Ser(P)-Pro-Arg-Ile-Glu-Ile-Thr-Ser-Cys-Leu. The phosphospecific NFATc1 antibody was affinity purified from the rabbit serum using standard techniques (17).

Binding assays. Cell extracts prepared using Triton-lysis buffer (20 mM Tris [pH 7.4], 137 mM NaCl, 2 mM EDTA, 1% Triton X-100, 25 mM β-glycerophosphate, 1 mM sodium vanadate, 2 mM sodium pyrophosphate, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 μg of leupeptin per ml) were incubated (5 h at 4°C) with recombinant proteins (5 μg) prebound to 20 μl of GSH-Sepharose. After three washes with Triton-lysis buffer, the bound proteins were detected by protein immunoblot analysis.

The c-Jun NH2-terminal kinase (JNK) group of mitogen-activated protein kinases is activated by treatment of cells with cytokines or exposure to environmental stress (19). Gene disruption studies indicate that JNK protein kinases are required for multiple biological processes (15, 23, 32, 41, 42). However, the molecular mechanisms that account for the phenotypes displayed by JNK knockout mice remain unclear. For example, the disruption of the Jnk1 gene causes a severe defect in the response of CD4+ helper T (Th1) cells to antigen-presenting cells (15). Wild-type naive Th1 cells can differentiate to Th1 or Th1/2 effector cells, which mediate inflammatory and humoral responses, respectively. In contrast, Jnk1−/− CD4 Th1 cells preferentially differentiate to Th1/2 effector cells and secrete large amounts of the Th2 cytokines, including interleukin-4 (IL-4). As a consequence, these mice are highly susceptible to infection with Leishmania. These effects of Jnk1 gene disruption were associated with increased nuclear accumulation of the NFATc1 transcription factor (15), which is known to act at the IL-4 promoter and is essential for Th2 responses (30, 44). The phenotype of Jnk1−/− mice suggests that NFATc1 is negatively regulated by JNK1 (15). However, this phenotype could be a direct or an indirect consequence of Jnk1 gene disruption.

The NFAT transcription factor was first identified as an important regulator of IL-2 gene expression (16, 20). More recently, it has been established that NFAT contributes to the expression of several cytokines and participates in multiple physiological processes (12, 31). In resting T cells, NFAT is restricted to the cytoplasm (12, 31). Following T-cell activation, a sustained increase in intracellular calcium (37) activates the protein phosphatase calcineurin (11, 21). The activated calcineurin dephosphorylates NFAT and leads to increased nuclear accumulation (12, 31). The nuclear NFAT transcription factor then increases the expression of target genes, including IL-2, IL-4, and Fas ligand.

The interaction of calcineurin with NFAT is a critical element in the signal transduction pathway that leads to increased NFAT-dependent gene expression. Interestingly, this interaction is mediated by a targeting domain (PxxIT motif) that is present in the NH2-terminal region of the NFAT transcription factor (1, 2, 8). This targeting domain is required for efficient NFAT activation in vivo. Furthermore, ectopic expression of the targeting domain causes profound and specific inhibition of NFAT-mediated gene expression in cultured cells (2, 8). Studies of transgenic mice also demonstrate inhibition of NFAT-mediated gene expression caused by expression of the calcineurin targeting domain (8). Together, these data indicate that the calcineurin targeting domain is a critical component of the regulatory mechanism that controls NFAT activity.

The purpose of this study was to examine the role of JNK1 in NFATc1 regulation. Since the phenotype of Jnk1−/− mice suggests a correlation between the JNK1 signaling pathway and NFATc1 (15), we tested whether NFATc1 is directly regulated by JNK1. We report that JNK1 binds and phosphorylates NFATc1 on sites located near the PxIxIT calcineurin targeting domain (8). This phosphorylation inhibits the interaction of calcineurin with the targeting domain and blocks nuclear accumulation. This observation provides a molecular mechanism for the observation of increased NFATc1 nuclear accumulation in Jnk1−/− mice.
FIG. 1. JNK1 inhibits NFAT activity in T cells. (A) Activation of JNK1 inhibits NFATc1 nuclear localization. Jurkat T cells were transfected without (empty expression vector; Control) and with MKK7 plus JNK1 (JNK). After 16 h, the cells were stimulated without (+) and with (-) ionomycin (I; 2 μM) plus PMA (P; 100 nM) for 6 h. Nuclear extracts were isolated (14), and NFATc1 was examined by protein immunoblot analysis using monoclonal antibody 7A6 (Affinity Bioreagents). Similar data were obtained in three independent experiments. (B) Activated JNK inhibits NFAT transcription activity. Jurkat T cells were transfected with an IL-4 promoter reporter gene (firefly luciferase) plasmid (Affinity Bioreagents). Similar data were obtained in three independent experiments.

Kinase assays. Hemagglutinin epitope (HA)-tagged JNK1 was coexpressed together with and without MLK3 in COS cells. Cell extracts were prepared with Triton-lysis buffer 48 h after transfection. JNK1 immunocomplex kinase assays were performed with recombinant NFATc1 proteins (1 μg) as the substrate (7).

Immunofluorescence assays. NIH cells were transfected using Lipofectamine (Life-Technologies Inc.) according to the manufacturer’s protocol. Immunofluorescence analysis was performed using cells transfected with an NFATc1 expression vector (1 μg) together with and without expression vectors for activated calcium (0.2 μg), MKK7 (0.2 μg) plus JNK1 (0.2 μg), dnJNK1 (0.5 μg), or JIP-1 (0.3 and 0.7 μg). NFATc1 proteins were detected using monoclonal antibody 7A6 (1:200; Affinity Bioreagents). The secondary antibody was Texas red-conjugated anti-mouse immunoglobulin antibody (1:100; Jackson Immuno-Research). Nuclei were visualized using 4,6-diamidino-2-phenylindole (Sigma).

RESULTS

JNK inhibits the nuclear accumulation of NFATc1-α. To test whether JNK1 regulates NFATc1, we examined the effect of activated JNK1 in transfection assays using cultured Jurkat T cells. Treatment with phorbol ester and ionomycin caused a transient increase in JNK protein kinase activity which returned to basal levels within 1 h (24, 35). At later times, a large increase in the expression of NFATc1 was detected (Fig. 1A). Cell fractionation studies demonstrated the presence of NFATc1 in the nucleus. Expression of activated JNK1 did not alter the expression of NFATc1 but did cause a marked reduction in the amount of nuclear NFATc1 (Fig. 1A). In contrast, expression of dnJNK1 increased the amount of nuclear NFATc1 caused by anti-CD3 stimulation (data not shown). Transfection assays were performed to examine the effect of JNK1 on transcription activity using an IL-4 promoter reporter gene. Activated JNK1, like dnNFAT, strongly inhibited reporter gene expression (Fig. 1B). Since constitutively nuclear mutant NFATc1 caused greatly increased reporter gene expression (data not shown), it is likely that the effect of activated JNK1 to inhibit reporter gene expression (Fig. 1B) was the consequence of the decreased amount of nuclear NFATc1 (Fig. 1A). Together, these data demonstrate that JNK1 functions as an inhibitor of the endogenous NFATc1 transcription factor expressed by Jurkat T cells.

Several alternatively spliced variant forms of NFATc1 have been described (9, 10, 18, 25, 26, 33). The major isofrom expressed by T cells has been identified as NFATc1-α (25, 33). We therefore performed further analysis of the regulation of NFATc1 by JNK using the NFATc1-α isoform.

JNK phosphorylates NFATc1-α. The JNK1 protein kinase binds and phosphorylates its substrates (19). Deletion analysis in vitro binding assays indicated that NFATc1-α residues 126 to 138 are required for the binding of NFATc1-α to JNK1 (Fig. 2). In contrast, NFATc1-α phosphorylation by JNK1 was reduced by truncation at residue 171 and was eliminated by truncation at residues 126 (Fig. 3A). Phosphoamino acid analysis demonstrated the presence of phosphoserine (data not shown). Four potential JNK1 phosphorylation sites (Ser-Pro motifs) were identified. Mutational analysis indicated that both Ser117 and Ser172 were phosphorylated by JNK1. Replacement of either Ser117 or Ser172 with Ala reduced phosphorylation by JNK1, while the replacement of both Ser117 and Ser172 eliminated phosphorylation by JNK1 (Fig. 3B). Together, these data demonstrate that JNK1 binds NFATc1-α and phosphorylates both Ser117 and Ser172 in vitro. The JNK1 phosphorylation site Ser172, but not Ser117, is conserved in the related transcription factor NFATc3 (7). Comparative tryptic phosphopeptide mapping of NFATc1-α isolated from [32P]phosphate-labeled cells indicated that two phosphopeptides present in maps of wild-type NFATc1-α were absent in maps of mutated [Ala117 Ala172]NFATc1-α suggesting that Ser117 and Ser172 may be phosphorylated in vivo (data not shown). To test this hypothesis, we prepared a phosho-NFATc1 antibody and performed immunoblot analysis of NFATc1-α. The phospho-NFATc1 antibody specifically detected phosphorylation on Ser117 (Fig. 4A). Activation of endogenous JNK caused increased NFATc1-α phosphorylation (Fig. 4B). Overexpression of the scaffold protein JIP-1 causes profound inhibition of JNK (13, 39) and inhibited NFATc1-α phosphorylation (Fig. 4B). Together, these data suggest that NFATc1-α is a JNK substrate in vivo.

Phosphorylation by JNK inhibits the nuclear accumulation of NFATc1-α. Studies of Jurkat T cells demonstrated that activated JNK1 inhibited the calcium-stimulated nuclear accumulation of NFATc1 (Fig. 1A). This observation was confirmed by immunofluorescence analysis of the subcellular distribution of NFATc1-α. Activated JNK1 inhibited the calcineurin-stimulated nuclear accumulation of NFATc1-α (Fig. 5A and B). This effect of activated JNK1 to inhibit NFATc1-α nuclear accumulation was blocked by overexpression of pro-
Proteins that can inhibit JNK signaling, including dnJNK1 (Figure 5C) and the scaffold protein JIP-1 (Fig. 5D). Together, these data demonstrate that activated JNK1 regulates NFATc1-a nuclear accumulation.

To test whether the phosphorylation of NFATc1-α is mechanistically relevant to the regulation of NFATc1-α nuclear accumulation by JNK1, we examined the effect of the replacement of the NFATc1-α phosphorylation sites with Ala residues. The subcellular distribution of the wild-type and mutated NFATc1-α proteins was examined by immunofluorescence analysis. Mutations at both phosphorylation sites (Ser117 and Ser172) altered the subcellular distribution of NFATc1-α. The mutated [Ala117 Ala172] NFATc1-α protein was found to be present in the nucleus under basal conditions and was not regulated by activated JNK1 (Fig. 5A and B). Mutation at either Ser117 or Ser172 was sufficient to increase the nuclear accumulation of NFATc1-α. To examine whether the altered nuclear accumulation of the phosphorylation-defective NFATc1-α proteins was relevant to transcription activity, we performed transfection assays of Jurkat T cells with an IL-4 promoter reporter plasmid (Fig. 5E). Expression of wild-type NFATc1-α using Jurkat T cells caused a large increase in phorbol myristate acetate (PMA)-ionomycin-stimulated IL-4 promoter reporter gene expression, which was inhibited by coexpression of activated JNK1. In contrast, the [Ala117 Ala172] NFATc1-α protein caused increased reporter gene expression in the absence of PMA-ionomycin stimulation and was not inhibited by activated JNK1 in the presence or absence of PMA-ionomycin (Fig. 5E). Together, these data demonstrate that the JNK1 phosphorylation sites (Ser117 and Ser172) are required for the regulation of both nuclear accumulation and transcription activity of NFATc1-α by JNK1.

**JNK selectively regulates NFATc1 isoforms.** We have previously reported that recombinant NFATc1 is not regulated by JNK1 (7). This conclusion markedly differs from the results obtained from the analysis of endogenous NFATc1 expressed by Jurkat T cells (Fig. 1). Several alternatively spliced variant forms of NFATc1 have been described, including molecules with three distinct COOH-terminal domains (9, 10) and three distinct NH2-terminal domains (18, 25, 26, 33). The isoforms

![Diagram](https://via.placeholder.com/150)
with distinct NH$_2$-terminal domains correspond to NFATc1 (18), NFATc1-$\alpha$ (25), and NFATc1-$\beta$ (26, 33). NFATc1-$\alpha$ is the major isoform expressed by T cells (25, 33).

To test whether JNK may differentially interact with NFATc1 isoforms, we expressed the NH$_2$-terminal region of NFATc1, NFATc1-$\alpha$, and NFATc1-$\beta$ in bacteria as glutathione S-transferase (GST) fusion proteins. The purified GST-NFAT proteins were immobilized on GSH-agarose. Control experiments demonstrated that JNK1 did not bind to immobilized GST (Fig. 6A). However, strong binding of JNK1 to NFATc1-$\alpha$ and NFATc1-$\beta$ was detected. In contrast, NFATc1 bound poorly to JNK1. In vitro immune complex protein kinase assays using epitope-tagged JNK1 demonstrated that there was greater phosphorylation of NFATc1-$\alpha$ and NFATc1-$\beta$ than of NFATc1 (Fig. 6B). These data suggest that JNK1 may be selectively targeted to NFATc1-$\alpha$ and NFATc1-$\beta$.

We compared the subcellular distribution of NFATc1, NFATc1-$\alpha$, and NFATc1-$\beta$ by immunofluorescence analysis (Fig. 6C). In control cells, NFATc1-$\alpha$ and NFATc1-$\beta$ were located predominantly in the cytoplasm, but a large fraction of NFATc1 was found in the nucleus. Expression of activated JNK1 caused no significant change in the subcellular distribution of these NFATc1 isoforms. In contrast, activated calcineurin caused increased nuclear localization of all three NFATc1 isoforms. Activated JNK1 suppressed the calcineurin-stimulated nuclear accumulation of NFATc1-$\alpha$ and NFATc1-$\beta$ but not the NFATc1 isoform. Taken together, these data indicate that JNK1 negatively regulates the NFATc1-$\alpha$ and NFATc1-$\beta$ isoforms but not the NFATc1 isoform.

Phosphorylation by JNK inhibits targeting of NFATc1-$\alpha$ by the phosphatase calcineurin. JNK1 phosphorylates NFATc1-$\alpha$ on Ser$^{117}$ and Ser$^{172}$ (Fig. 3). Ser$^{117}$ of NFATc1-$\alpha$ is located adjacent to the previously identified calcineurin targeting domain (PdxIT motif) (1, 8). We hypothesized that phosphorylation on Ser$^{117}$ may regulate the targeting of NFATc1-$\alpha$ to calcineurin. However, the proximity of Ser$^{172}$ to the calcineurin targeting domain suggests that Ser$^{172}$ may represent a potential substrate for dephosphorylation by calcineurin. We there-
fore examined the kinetics of calcineurin-mediated dephosphorylation of JNK1-phosphorylated NFATc1-α. This analysis demonstrated that Ser^{172} (and not Ser^{117}) was preferentially dephosphorylated by calcineurin in vitro (Fig. 7A). Thus, the PxIxIT targeting motif that binds calcineurin facilitates the dephosphorylation of distal (e.g., Ser^{172}) but not proximal (e.g., Ser^{117}) NFAT phosphorylation sites. These data support the hypothesis that Ser^{117} may regulate the targeting function of the NFATc1-α PxIxIT motif. To test this hypothesis, we examined the effect of NFATc1-α phosphorylation by JNK1 on the interaction of NFATc1-α with calcineurin. Phosphorylation caused a marked reduction in the binding of calcineurin to NFATc1-α (Fig. 7B). Mutational analysis demonstrated that the phosphorylation of Ser^{117}, but not Ser^{172}, was required for the regulation of calcineurin binding by JNK1. To confirm that phosphorylation on Ser^{117} regulates calcineurin binding, we performed competition assays using a synthetic PxIxIT peptide with either Ser^{117} or phospho-Ser^{117} (Fig. 7C). Binding assays confirmed that the Ser^{117} PxIxIT peptide disrupted calcineurin binding in a dose-dependent manner. In contrast, calcineurin binding to NFATc1-α was not inhibited by the phospho-Ser^{117} PxIxIT synthetic peptide. Together, these data demonstrate that Ser^{117} phosphorylation inhibits the function of the calcineurin targeting domain of NFATc1-α.

CRM1 interacts with dephosphorylated NFATc1-α. The export of NFAT from the nucleus is mediated, in part, by a mechanism that involves the ATPase Ran and the exportin CRM1 (22). One CRM1 binding site on NFATc3 is located adjacent to the calcineurin targeting domain (45). Indeed, binding of NFATc3 to calcineurin competes with the binding to CRM1 (45). Since NFATc1-α phosphorylation inhibits the binding of calcineurin (Fig. 7), we examined whether phosphorylation affected the interaction of NFATc1-α with CRM1. Binding assays were performed using immobilized GST-CRM1 and lysates prepared from COS cells expressing NFATc1-α (Fig. 8). We found that NFATc1-α bound to CRM1. The binding to CRM1 was increased when the NFATc1-α was coexpressed with activated calcineurin (Fig. 8A).
Phosphorylation of Ser\(^{117}\) inhibits calcineurin binding to NFATc1-\(\alpha\). Inhibition of calcineurin by JNK1 inhibits the binding of NFATc1-\(\alpha\) to CRM1. Overexpression of the scaffold protein JIP-1 caused a profound inhibition of JNK signaling (13, 39). JIP-1 increased the binding of CRM1 to wild-type Ser\(^{117}\) and Ser\(^{172}\) NFATc1-\(\alpha\) but not to the mutated phosphorylation-defective Ala\(^{117}\) and Ala\(^{172}\) NFATc1-\(\alpha\). These data indicate that phosphorylation regulates the interaction between CRM1 and NFATc1-\(\alpha\).

**DISCUSSION**

In this study, we demonstrate that the JNK1 signaling pathway plays a key role as a negative regulator of substrate targeting by the phosphatase calcineurin. The phosphorylation of NFATc1-\(\alpha\) by JNK provides a mechanism whereby NFATc1-\(\alpha\)-driven responses can be terminated, which can set a threshold for a given response. This is likely to be important for normal cellular physiology. Indeed, we have demonstrated that Jnk1-\(\alpha\) mice display enhanced T\(_H2\) responses due to increased nuclear localization of NFATc1 (15). Conversely, activation of the JNK1 signaling pathway inhibits IL-4 gene promoter activity (Fig. 1). Thus, JNK1 functions in T\(_H2\) cells to suppress the expression of cytokines that enhance T\(_H2\) responses (e.g., IL-4) which would otherwise lead to the generation of an unbalanced T\(_H1\) cell immune response to pathogens. Together, the genetic evidence and biochemical analysis that we present strongly support the hypothesis that JNK is a physiologically relevant regulator of NFATc1-\(\alpha\) function.

Recent studies have established that the formation of protein complexes is a critical aspect of signal transduction mechanisms that ensures both efficiency and specificity in vivo (27, 40). An example of the formation of signaling complexes is the requirement of targeting domains for the interaction of protein kinases and protein phosphatases with their substrates. We demonstrate that such interactions are subjected to regulation by phosphorylation. Our results indicate that phosphorylation of NFATc1-\(\alpha\) by JNK inhibits targeting of the phosphatase calcineurin. Since calcineurin functions to induce the nuclear accumulation of NFAT, phosphorylation by JNK inhibits NFATc1-\(\alpha\) activation. Inhibition of phosphatase targeting

To test whether phosphorylation of NFATc1-\(\alpha\) on the JNK sites altered CRM1 binding, we examined the effect of replacement of Ser\(^{117}\) and Ser\(^{172}\) with Ala residues. A marked increase in NFATc1-\(\alpha\) binding to CRM1 was detected for the mutated, phosphorylation-defective NFATc1-\(\alpha\)-protein (Fig. 8B). These data suggested that phosphorylation on Ser\(^{117}\) and Ser\(^{172}\) may inhibit binding to CRM1. To test this hypothesis, we examined the effect of inhibiting JNK signaling on the binding of NFATc1-\(\alpha\) to CRM1. Overexpression of the scaffold protein JIP-1 causes a profound inhibition of JNK signaling (13, 39). JIP-1 increased the binding of CRM1 to wild-type Ser\(^{117}\) and Ser\(^{172}\) NFATc1-\(\alpha\) but not to the mutated phosphorylation-defective Ala\(^{117}\) and Ala\(^{172}\) NFATc1-\(\alpha\). These data indicate that phosphorylation regulates the interaction between CRM1 and NFATc1-\(\alpha\).
is a novel mechanism of regulation by a mitogen activated protein kinase. However, this regulatory mechanism may also be applicable to other signaling systems that are regulated by phosphorylation.

Our study further establishes the importance of the PxIxIT motif in the regulation of calcineurin targeting to NFAT. Previous studies demonstrated that the PxIxIT motif was required for efficient activation of NFAT by calcineurin (1) and that ectopic expression of the PxIxIT motif inhibits NFAT-mediated gene expression in both cultured cells (2, 8) and transgenic mice (8). Here we demonstrate that the function of the PxIxIT targeting motif can be regulated by phosphorylation. Our data suggest that regulated substrate targeting represents a potential approach for the design of novel therapeutic agents.

Coordination of NFAT binding to calcineurin and CRM1. It is established that both the phosphatase calcineurin and the exportin CRM1 bind to NFAT (22, 45). Studies of NFATc3 indicate that one of the binding sites for CRM1 is located adjacent to the calcineurin binding site (45). Binding to calcineurin is calcium dependent and competes with the binding to CRM1. The binding affinity of NFATc3 for calcineurin/ Ca2+ is higher than that for CRM1 (45). These observations have led to the conclusion that calcineurin acts, in part, to induce nuclear accumulation of NFATc3 by suppressing the CRM1-dependent export pathway (45). It is likely that other NFAT proteins are regulated by similar mechanisms.

Our studies of NFATc1-α indicate that phosphorylation by JNK causes inhibition of calcineurin binding (Fig. 7). This inhibited interaction with calcineurin may account for the effect of activated JNK to prevent calcium-mediated nuclear accumulation of NFATc1-α (Fig. 5). Since calcineurin and CRM1 compete for binding to NFAT, we considered that the effect of JNK to decrease calcineurin binding might lead to increased CRM1 binding. This potential mechanism suggests that increased CRM1-mediated export of NFATc1-α from the nucleus may contribute to the effect of JNK signaling to inhibit nuclear accumulation of NFATc1-α. However, measurement of CRM1 binding demonstrated that JNK phosphorylation inhibited the binding of both CRM1 and calcineurin (Fig. 7 and 8). These data suggest that the primary action of JNK to prevent the nuclear accumulation of NFATc1-α is inhibition of calcineurin binding.

Regulation of NFAT subcellular distribution by phosphorylation. The NFAT transcription factors are phosphoproteins that are located in the cytosol of resting cells. Upon dephosphorylation by the phosphatase calcineurin, NFAT accumulates in the nucleus (12, 31). Conversely, phosphorylation of NFAT isoforms opposes nuclear accumulation. NFAT phosphorylation has been shown to be mediated by many different protein kinases (3, 5–7, 29, 34, 46). The relative importance and physiological significance of each of the protein kinases remains to be established.

The role of NFAT phosphorylation is unclear, but it is likely that different sites of phosphorylation will regulate different biological functions. Here we report that the phosphorylation of NFATc1-α by JNK causes inhibition of calcineurin targeting to the PxIxIT motif (Fig. 7). Previous studies indicate that phosphorylation on the Ser-rich region facilitates intramolecular interaction with the COOH-terminal nuclear localization sequence (NLS2) of NFATc1 (4). Phosphorylation-dependent intramolecular interaction within the NFAT homology region has also been proposed to regulate NFATc3 subcellular distribution (46). Furthermore, NFAT phosphorylation facilitates intermolecular interaction with 14-3-3 adapter proteins (6). Binding to 14-3-3 masks the NH2-terminal NLS1 and may regulate NFAT subcellular distribution. These data indicate that phosphorylation regulates multiple NFAT intermolecular and intramolecular interactions that contribute to the shuttling of NFAT isoforms between the nuclear and cytoplasmic compartments of the cell. Further studies of NFAT phosphorylation are required before we can obtain a complete understanding of the mechanism of regulation of NFAT nuclear accumulation.

Role of JNK-regulated NFATc1-α activity. NFATc1-α and NFATc2 represent the major NFAT isoforms expressed by T cells. NFATc1-α (Fig. 1), but not NFATc2 (7), is negatively regulated by JNK. This observation raises an important question concerning the physiological function of JNK as an NFAT inhibitor. Studies of primary naive peripheral T cells indicate that NFATc1-α is expressed at very low levels, but the expression of NFATc1-α is induced following T-cell activation (20, 33). In contrast, NFATc2 is expressed at high levels both before and after T-cell activation (20). This pattern of expression suggests that JNK is not a significant regulator of NFAT activity in naive T cells or in T cells at early times following activation. However, a role for JNK as an inhibitor of NFAT activity at late times following T-cell activation is implicated.

The possible role for JNK as an NFAT inhibitor at late times following T-cell activation is consistent with the results of a recent report that examined JNK expression by T cells (38). JNK1 and JNK2 were found to be expressed at very low levels in naive peripheral CD4+ T cells. Similarly, the JNK activators MKK4 and MKK7 were found to be expressed at low levels. Activation mediated by the T-cell receptor plus the CD28 coreceptor caused a marked induction of mRNA and protein expression of JNK1, JNK2, MKK4, and MKK7 that peaked at approximately 24 h following T-cell activation. The peak of expression correlated with increased JNK activity in the activated T cells. Together, these data indicate that the JNK signaling pathway in T cells is induced during T-cell activation. This temporal pattern of expression of the JNK signaling pathway components is similar to that of NFATc1-α. The extremely low level of expression of NFATc1-α and JNK pathway components in naive peripheral CD4+ T cells strongly argues against a role for JNK during the early phase of T-cell activation.

The considerations outlined above indicate that the function of JNK to inhibit NFATc1-α most likely occurs at late times following T-cell activation (e.g., 24 h). We propose that JNK functions to provide a tonic inhibitory signal that opposes NFATc1-α activation and expression of downstream target genes (e.g., IL-4). JNK may therefore provide a threshold for the maintenance of T-cell responses by requiring higher levels of stimulatory signals. This mechanism is consistent with the observation that Jnk1−/−/CD4+ T cells are hyperresponsive to stimulatory signals, including enhanced production of IL-4 (15). This role of JNK in setting a threshold for T-cell activation may contribute to tolerance and the initiation of an immune response.

ACKNOWLEDGMENTS

The first two authors contributed equally to this work.

We thank G. R. Crabtree, J. S. Gutkind, T. Hoey, S. Kornbluth, K. M. Murphy, and T. Soderling for providing reagents; C. Turck for peptide synthesis; T. Barrett, A. Quail, and J. Stein for technical assistance; and K. Gemme for administrative assistance.

C.-W. Chow is an Arthritis Foundation fellow. This work was supported in part by grants CA65861 and CA72009 and by the Howard Hughes Medical Institute.

REFERENCES


